Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Conditions
Urothelial Cancer · Urinary Bladder Neoplasms
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Samsun Clinic - Ridley-Tree Cancer Center, Santa Barbara, California, United States
Medical Oncology Hematology Consultants, Newark, Delaware, United States
Illinois Cancer Specialists, Niles, Illinois, United States
Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
Missouri Cancer Associates, Columbia, Missouri, United States
Williamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States
Compass Oncology - West, Tigard, Oregon, United States
SCRI Oncology Partners, Nashville, Tennessee, United States
Texas Oncology, Austin, Texas, United States
Texas Oncology - Northeast Texas, Tyler, Texas, United States
Virginia Oncology Associates, Norfolk, Virginia, United States
Study leads
Zejing Wang, MD/PhD
Study Director
Pfizer